Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538636 · ClinicalTrials.gov registry record · NA
Prediction Augmented Screening Initiative
A NA study, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 23,520
- Enrollment target
NCT06538636: Recruiting NA study, sponsored by VA Office of Research and Development.
NCT06538636 is a NA study that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 23,520 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538636, a NA study, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 23,520 participants
- Enrollment target
Study Summary
Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds cancer at an earlier stage when it is curable, yet only 20% of eligible Veterans have been screened. Uptake is even lower among Black Veterans despite higher lung cancer risk. Using prediction models to identify high-benefit people for whom LCS should be encouraged improves efficiency and reduces disparities. Moreover, it is more patient-centered as shared decision-making conversations can be tailored with personalized information. The US Preventive Services Task Force has called for research to demonstrate that prediction-augmented LCS can be feasibly implemented at the point-of-care. The investigators propose for VA to lead this effort with a large-scale pragmatic clinical trial to show that prediction-augmented LCS is both feasible and improves LCS uptake.
Interventions
- OTHER PCP-Facing Tools
- OTHER LCS team population management tools
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23,520 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06538636
The ClinicalTrials.gov registry entry for NCT06538636 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 23,520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PCP-Facing Tools is the first listed.
NCT06538636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06538636 about?
NCT06538636 is a clinical study titled "Prediction Augmented Screening Initiative". Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds ca...
What is the current status of trial NCT06538636?
This trial is currently recruiting. It is a NA study. The enrollment target is 23,520 participants. The study started on 2026-06-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT06538636?
The interventions under investigation include: PCP-Facing Tools (OTHER), LCS team population management tools (OTHER).
Who is sponsoring clinical trial NCT06538636?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.